40 og 50, 0 x 109/ l) sås hos 29% af patienterne i 14% af behandlingsperioderne.
Moderate thrombocytopenia (Grade 3 - platelets between 10.0 and 50.0 x 109/ l) occurred in 29% of patients in 14% of courses.